| Name | Title | Contact Details |
|---|
Arzeda The Protein Design Company is a synthetic biology company.
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.
CellMax Life is revolutionizing early cancer detection, prevention and management.
ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Macherey-Nagel is a Easton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.